Tryptamine Therapeutics Ltd
TYP
Company Profile
Business description
Tryptamine Therapeutics Ltd is a clinical-stage biotechnology company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. Its product pipeline includes TRP-8803 (IV-infused psilocin) and TRP-8802 (oral psilocybin).
Contact
C/o Bio101 Financial Advisory Pty Ltd
697 Burke Road, Suite 201
Camberwell
MelbourneVIC3124
AUST: +61 390920475
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
50
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,741.90 | 26.70 | -0.30% |
| CAC 40 | 7,804.87 | 14.60 | 0.19% |
| DAX 40 | 24,304.46 | 19.12 | -0.08% |
| Dow JONES (US) | 42,762.87 | 443.13 | 1.05% |
| FTSE 100 | 8,837.91 | 26.87 | 0.30% |
| HKSE | 23,792.54 | 114.43 | -0.48% |
| NASDAQ | 19,529.95 | 231.51 | 1.20% |
| Nikkei 225 | 37,741.61 | 187.12 | 0.50% |
| NZX 50 Index | 12,563.48 | 13.67 | -0.11% |
| S&P 500 | 6,000.36 | 61.06 | 1.03% |
| S&P/ASX 200 | 8,515.70 | 23.20 | -0.27% |
| SSE Composite Index | 3,385.36 | 1.26 | 0.04% |